
    
      Subjects meeting inclusion/exclusion criteria will be randomly assigned to: (1) the treatment
      group where antiplatelet medications will be selected using platelet function phenotype
      and/or key pharmacogene genotypes (2) the control group where participants will receive
      standard care for antiplatelet therapy (without knowledge of phenotype or genotype).
    
  